Discover

Back to filter

Related topics

Discover the Celloger live-cell analyzers : miniaturized and powerful tools for every Biologist

Curiosis

Apr 5, 2024

Celloger live-cell analyzers, image and analyze your cells in real-time, inside your incubator. With its exceptional...

The chicken chorioallantoic membrane as a low-cost, high-throughput model for cancer imaging

Precision X-Ray

Apr 4, 2024

Here, we assessed the chicken chorioallantoic membrane (CAM) as an alternative to mice for preclinical cancer imaging...

A microthrombus-driven fixed-point cleaved nanosystem for preventing post-thrombolysis recurrence

IVIM Technology

Apr 3, 2024

A thrombin-responsive and fixed-point cleaved Fu@pep-CLipo was developed for highly efficient and precise thrombolysis...

Multiplexed tissue imaging using the Orion platform to reveal the Spatial Biology of Cancer

RareCyte

Mar 27, 2024

In this webinar Prof. Sandro Santagata, will reveal how Orion high-plex imaging and the use of this data, is valuable...

Cytek SpectroFlo Software Version 3.3 has been released!

Cytek Biosciences

Mar 25, 2024

SpectroFlo Software Version 3.3 has been released, enabling new assays with SpectroFlo Software version 3.3, including...

Innovation is in its DNA

Mission Bio

Mar 22, 2024

Mission Bio’s Tapestri Tool May Hold the Key to Informing Treatment Options for Multiple Myeloma.

A 19-color single-tube Full Spectrum Flow Cytometry for the detection of Acute Myeloid Leukemia

Cytek Biosciences

Mar 13, 2024

This recent publication in Cytometry Part A describes the development and comprehensive workflow of a single-tube,...

18F-labeled somatostatin analogs for somatostatin receptors (SSTRs) targeted PET imaging of NETs

MOLECUBES

Mar 11, 2024

A novel 18F-radiolabeled somatostatin analogue, [Al18F]NODA-MPAA-HTA, was synthesized and evaluated for positron...

Discover Yokogawa CellVoyager CQ1: Benchtop High-Content Analysis System

Yokogawa

Mar 8, 2024

Unlike flow cytometers, the CellVoyager CQ1 confocal quantitative image cytometer does not require pretreatment such as...

Real-time and quantitative analysis of Macrophage Phagocytosis with RTCA eSight

Agilent technologies

Feb 23, 2024

The eSight is currently the only instrument that interrogates cell health and behavior using cellular
impedance
...

Show all topics (10)

Preclinical cardiac safety assesment

Mar 22, 2016

Over the last two decades, a number of blockbuster drugs have been withdrawn or have incurred safety warnings by regulatory agencies due to adverse cardiac effects. In addition, lead compounds or drug candidates are frequently terminated at late stages of drug development due to cardiac safety concerns. Both of these factors can significantly impact the overall cost of drug discovery; consequently, pharmaceutical companies and regulatory agencies have implemented procedures to address these issues.

Most, if not all, in vitro assay systems for cardiac safety are designed to screen for surrogates of arrhythmia, such as hERG channel interaction, rather than arrhythmia itself. Assays designed to screen for compounds that may affect repolarization and induce arrhythmia in the context of the whole heart or heart tissue are not implemented until much later in drug development. These include sophisticated, technically demanding, lowthroughput, and costly procedures such as the Purkinje fiber assay, ventricular wedge assay, and the Langendorff whole heart assay, or telemetry experiments in live and anesthetized animals. The field of preclinical cardiac safety can certainly benefit from an assay system that allows for integrated assessment of compound action on ion channel and non-ion channel targets involved in cardiac excitation-contraction coupling.

The RTCA Cardio Instrument in conjunction with iCell Cardiomyocytes comprises an assay system providing integrated assessment of compound action on multiple targets involved in heart function. This assay system can sensitively and quantitatively detect the effect of compounds on the major ion channels involved in heart function, namely calcium, sodium, and potassium channels. Another major advantage of the assay system is the time resolution. The RTCA Cardio Instrument has a data acquisition rate of 12.5 ms per well of a 96-well plate and can be used simultaneously to monitor acute and chronic drug effects up to days and weeks. The utility of the time-dependent monitoring of compound action on cardiomyocytes can be demonstrated by testing compounds that acutely and directly block hERG channels (E4031, cisapride, etc.) and compounds that interfere with protein trafficking (pentamidine) in a sub-chronic manner. The RTCA Cardio Instrument is able to detect the effects of these compounds on the beating rate and duration of iCell Cardiomyocytes.

The xCELLigence System RTCA Cardio Instrument, in conjunction with iCell Cardiomyocytes, represents a physiologically relevant and predictive assay system for preclinical cardio-safety assessment of lead compounds. The features of this assay system, including time resolution, dynamic monitoring of mechanical beating activity of cardiomyocytes, and 96-well throughput, will surely provide additional mechanistic and toxicity information for compound action on the heart.

Application
Product news

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

Cardio Instrument is a high-resolution system for label-free-dual-mode monitoring of cardiomyocyte and cardiotoxicity testing

show detail

The new CardioECR system combines impedance and Multi Electrode Array (MEA) technology with a pacing function

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey